Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

Summary

The post-trial access program allows eligible participants to gain access to unlicensed treatment on compassionate grounds. Recombinant von Willebrand factor (rVWF) also known as TAK-577, is a medicine to help treat Von Willebrand Disease (VWD). This post-trial access program enables continued access to children and adults who are benefitting from treatment on study SHP677-304 (NCT03879135) study.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications